These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30617005)

  • 1. Poor adherence to population-based vaccination in two counties after meningococcal B:14:P1.7,16 outbreak: an illustration of the growing vaccine hesitancy in France.
    Cabasson S; Roux J; Charron M; Sarlangue J; Debeugny S; Jouhet V; Monlun E
    Arch Pediatr; 2019 Feb; 26(2):75-79. PubMed ID: 30617005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination.
    Thabuis A; Tararbit K; Taha MK; Dejour-Salamanca D; Ronin V; Parent du Chatelet I; Spaccaferri G
    Euro Surveill; 2018 Jul; 23(28):. PubMed ID: 30017022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Tsang R; Law D; De Serres G; Gilca V; Gilca R; Boulianne N
    Clin Infect Dis; 2017 May; 64(9):1263-1267. PubMed ID: 28207068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak.
    Caron F; du Châtelet IP; Leroy JP; Ruckly C; Blanchard M; Bohic N; Massy N; Morer I; Floret D; Delbos V; Hong E; Révillion M; Berthelot G; Lemée L; Deghmane AE; Bénichou J; Lévy-Bruhl D; Taha MK
    Lancet Infect Dis; 2011 Jun; 11(6):455-63. PubMed ID: 21489881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination campaign following an increase in incidence of serogroup C meningococcal diseases in the department of Puy-de-Dôme (France).
    Lévy-Bruhl D; Perrocheau A; Mora M; Taha MK; Dromell-Chabrier S; Beytout J; Quatresous I
    Euro Surveill; 2002 May; 7(5):74-6. PubMed ID: 12631934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 7. Durability of immunogenicity and strain coverage of MenBvac, a meningococcal vaccine based on outer membrane vesicles: Lessons of the Normandy campaign.
    Sevestre J; Hong E; Delbos V; Terrade A; Mallet E; Deghmane AE; Lemée L; Taha MK; Caron F
    Vaccine; 2017 Jul; 35(32):4029-4033. PubMed ID: 28624305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.
    Izquierdo G; Torres JP; Santolaya ME; Valenzuela MT; Vega J; Chomali M
    Hum Vaccin Immunother; 2015; 11(4):875-83. PubMed ID: 25714390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted vaccination campaigns of teenagers after two clusters of B invasive meningococcal disease in Brittany, France, 2017.
    Pivette M; Taha MK; Barret AS; Polard E; Hautier MB; Dufour JB; Faisant M; King LA; Antona D; Levy-Bruhl D; Tillaut H; Scanff A; Morival C; Aranda Grau JH; Guillaumot P; Gagnière B
    BMC Public Health; 2020 Sep; 20(1):1382. PubMed ID: 32912190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.
    De Serres G; Billard MN; Gariépy MC; Rouleau I; Toth E; Landry M; Boulianne N; Gagné H; Gilca V; Deceuninck G; Ouakki M; Skowronski DM
    Vaccine; 2018 Dec; 36(52):8039-8046. PubMed ID: 30467063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022.
    Rodrigues CMC; MacDonald L; Ure R; Smith A; Cameron JC; Maiden MCJ
    mBio; 2023 Apr; 14(2):e0049923. PubMed ID: 37036356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England.
    Ladhani SN; Andrews N; Parikh SR; Campbell H; White J; Edelstein M; Bai X; Lucidarme J; Borrow R; Ramsay ME
    N Engl J Med; 2020 Jan; 382(4):309-317. PubMed ID: 31971676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Invasive meningococcal disease in the Czech Republic - analysis of the epidemiological situation and vaccination strategy recommendations].
    Křížová P; Vacková Z; Musílek M; Kozáková J
    Epidemiol Mikrobiol Imunol; 2013 Dec; 62(4):138-47. PubMed ID: 24467175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine-preventable severe morbidity and mortality caused by meningococcus and pneumococcus: A population-based study in France.
    Lorton F; Chalumeau M; Assathiany R; Martinot A; Bucchia M; Roué JM; Bourgoin P; Chantreuil J; Boussicault G; Gaillot T; Saulnier JP; Caillon J; Levy C; Cohen R; Gras-Le Guen C; Launay E
    Paediatr Perinat Epidemiol; 2018 Sep; 32(5):442-447. PubMed ID: 30170336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
    de Moraes JC; Perkins BA; Camargo MC; Hidalgo NT; Barbosa HA; Sacchi CT; Landgraf IM; Gattas VL; Vasconcelos Hde G
    Lancet; 1992 Oct; 340(8827):1074-8. PubMed ID: 1357461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MeNZB vaccine and epidemic control: when do you stop vaccinating?
    Loring BJ; Turner N; Petousis-Harris H
    Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
    Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
    Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Mass Vaccination Clinics in Response to a Serogroup B Meningococcal Disease Outbreak at a Large, Public University-Oregon, 2015.
    Fisher EA; Poissant T; Luedtke P; Leman R; Young C; Cieslak P
    J Adolesc Health; 2018 Aug; 63(2):151-156. PubMed ID: 30149923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.